TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage immuno-oncology company, has announced significant advancements in its global intellectual property portfolio, securing patent protections in Australia and Japan for its RNA-based cancer therapies. These developments underscore the company's commitment to protecting its innovative technologies and could bolster its position in the competitive landscape of RNA therapeutics.
The Australian patent acceptance, granted by IP Australia for Patent Application No. 2019349817, covers therapeutic nanoparticle compositions designed to deliver small interfering RNA (siRNA) molecules for cancer treatment. The allowed claims encompass nanoparticle compositions and methods of use across a range of cancers, including colon, lung, breast, pancreatic, and ovarian cancers. With a projected expiration date of September 6, 2039, this patent provides long-term exclusivity for TransCode's siRNA delivery platform in a key market. The ability to deliver siRNA effectively is a major challenge in RNA therapeutics, and this patent reinforces TransCode's proprietary position in the field, potentially enabling partnerships or licensing opportunities.
In Japan, the company received a Notice of Allowance from the Japan Patent Office, followed by the grant and issuance of Japanese Patent No. 7886877. This patent covers RNA-based immunomodulatory compositions designed to selectively activate innate immune pathways within tumors and the tumor microenvironment. The claims include compositions targeting cancers expressing miR-21, a microRNA implicated in various cancers, and nanoparticle-enabled delivery approaches incorporating magnetic or polymer-coated systems. This patent is particularly significant as it protects a novel approach to immuno-oncology that could complement existing therapies and address unmet needs in hard-to-treat cancers.
These patent milestones are crucial for TransCode Therapeutics as they validate the company's innovative research and provide a foundation for future commercialization. The global patent portfolio expansion not only protects the company's intellectual property but also enhances its attractiveness to investors and potential partners. In the highly competitive biotech sector, a robust IP portfolio is often a key differentiator and can drive valuation. For TransCode, these patents could facilitate strategic collaborations or out-licensing deals, providing non-dilutive funding to advance its pipeline.
TransCode's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis. The company also has a portfolio of other first-in-class therapeutic candidates aimed at mobilizing the immune system to recognize and destroy cancer cells. The recent patent allowances align with TransCode's mission to pioneer RNA therapeutics for high-risk and advanced cancers.
Investors and industry observers can find more details on the full press release at https://ibn.fm/Pqy4e. For ongoing news and updates about TransCode Therapeutics, visit the company's newsroom at https://ibn.fm/RNAZ. Additionally, more information about TransCode Therapeutics is available at TransCode Therapeutics (NASDAQ: RNAZ).
The announcement was disseminated through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication and other services to help companies reach a wide audience. For more information on their services, including editorial syndication to 5,000+ outlets and social media distribution, visit their website. Please review the full terms of use and disclaimers at https://www.InvestorWire.com/Disclaimer.
